Risultati della ricerca - Verheul, Henk M. W.
- Mostra 1 - 20 risultati su 96
- Vai alla pagina seguente
-
1
-
2
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? di Gotink, Kristy J., Verheul, Henk M. W.
Pubblicazione 2009testo -
3
-
4
-
5
-
6
-
7
-
8
Reply to L.E. Daly et al di Blauwhoff-Buskermolen, Susanne, de van der Schueren, Marian A.E., Langius, Jacqueline A.E., Verheul, Henk M.W.
Pubblicazione 2016testo -
9
-
10
-
11
A Multiple Loop, Double Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors di Kortenhorst, Madeleine S. Q., Zahurak, Marianna, Shabbeer, Shabana, Kachhap, Sushant, Galloway, Nathan, Parmigiani, Giovanni, Verheul, Henk M.W., Carducci, Michael A.
Pubblicazione 2008testo -
12
-
13
-
14
Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled tria... di van der Vorst, Maurice J. D. L, Neefjes, Elisabeth C. W., Konings, Inge R. H. M., Verheul, Henk M. W.
Pubblicazione 2015testo -
15
-
16
-
17
-
18
-
19
CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer di Gootjes, Elske C., Kraan, Jaco, Buffart, Tineke E., Bakkerus, Lotte, Zonderhuis, Barbara M., Verhoef, Cornelis, Verheul, Henk M.W., Sleijfer, Stefan
Pubblicazione 2020testo -
20
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance di Honeywell, Richard J., Kathmann, Ietje, Giovannetti, Elisa, Tibaldi, Carmelo, Smit, Egbert F., Rovithi, Maria N., Verheul, Henk M.W., Peters, Godefridus J.
Pubblicazione 2020testo